Press Releases

Back to all press releases

National Brain Tumor Society Appoints David Arons Interim Chief Executive Officer

2015-07-15

National Brain Tumor Society (NBTS), the largest nonprofit dedicated to the brain tumor community in the United States, has today appointed David Arons, JD, as interim Chief Executive Officer. Mr. Arons has served as Chief Public Policy and Advocacy Officer at the National Brain Tumor Society for the past four years.

“We are excited to have David Arons lead the National Brain Tumor Society as we continue our search for a full-time chief executive,” said Michael Nathanson, Chairman of the Board of Directors. “In his time with the organization, David has proven himself to be an adept leader who truly understands the brain tumor community, its needs, and the systemic change required to drive greater progress toward our mission of better treatments and ultimately a cure for brain tumors.”

As the chief executive, Mr. Arons will steward the organization’s operations and programmatic initiatives and maintain a consistent focus on aligning NBTS’ research, policy, and fundraising efforts with its strategic plan and aggressive targets for growth.

Before his work at NBTS, he served as director of government relations for the American Cancer Society in Minnesota. He is the author of several books, including Power in Policy: A Funder’s Guide to Advocacy and Civic Participation, Strengthening Nonprofit Advocacy, and A Voice for Nonprofits. He also serves on the National Cancer Institute’s Council of Research Advocates and Clinical Trials Advisory Committee.

“I am honored to take on this leadership role and continue the amazing work of this team of talented professionals and volunteers,” said Mr. Arons. “I believe that the National Brain Tumor Society is uniquely positioned to be a catalyst for change in the brain tumor community and that our acute focus on our mission, combined with the dedicated work of the many researchers, clinicians, volunteers and advocates, will help us achieve the impact that brain tumor patients and their loved ones need and deserve.”

Share